Greenwich Lifesciences Inc. followed a February update with another on the phase III Flamingo-01 trial, providing open-label immune response data for GLSI-100, a HER2/neu peptide vaccine immunotherapy ...

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj ® (revumenib), an ...

FORT LAUDERDALE, FL / ACCESS Newswire / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a ...

Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to ...

Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my ...

In April 2025, Actelion announced a study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the ...

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating ...

Detailed price information for Sunshine Biopharma (SBFM-Q) from The Globe and Mail including charting and trades.

Expression of granulocyte macrophage colony stimulating factor peaked immediately after each cretostimogene instillation according to urine samples and the local effect was sustained for 4-5 days.

FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ...

Teacher Retirement System of Texas lifted its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 18.7% during the 4th quarter, HoldingsChannel.com reports. The institutional ...